Purpose: To describe cardiac transplantation in a young woman with juvenile onset diffuse scleroderma and cardiac involvement. Methods: Case report. results: A young White girl developed anti-topoisomerase-1 positive diffuse scleroderma aged 14 years with myositis. Pulmonary function tests were normal. Skin disease was treated with mycophenolate mofetil 1 g twice daily, methotrexate 7.5 mg weekly and periodic intravenous prostacyclin. When aged 17 years, she developed raised troponin T of 0.207 mcg/L (normal range <0.03) and NTproBNP (155 pmol/L); 6-min walking distance was 341 m, and she had episodes of presyncope with effort. The next year she developed symptomatic ventricular tachycardias and dual-chamber implantable cardioverter-defibrillator was inserted, with further episodes of ventricular tachycardia and one shock delivered. By age 19 years, 6-min walking distance was 125 m. Echocardiography showed ejection fraction of 15%-20% with dilated left ventricle and pericardial effusion. She was treated with intravenous Rituximab. She became breathless while dressing and managed only 118 m in 6 min. She experienced increasing orthopnoea and peripheral oedema and was found to be in a low cardiac output state, requiring treatment with intravenous milrinone to maintain renal function. She underwent orthotopic cardiac transplantation, making an excellent post-operative recovery, and was discharged 16 days later with tacrolimus, mycophenolate mofetil and prednisolone. After 1 year, she was in New York Heart Association functional class I and with normal cardiac function on echocardiography. Conclusion: This case illustrates the severe cardiac involvement that can occur in juvenile onset diffuse cutaneous systemic sclerosis, in which cardiac involvement is the leading cause of death.
Introduction
Cardiac scleroderma is a rare complication of juvenile onset scleroderma, affecting about 3% of patients reaching adulthood in one study (1) , and is a major cause of mortality, being present in 50% of children who died from the disease (2) . We describe novel investigation, including use of positron emission tomography-computed tomography (PET-CT), failure of medical treatment, including cyclophosphamide and Rituximab and ultimately requiring orthotic cardiac transplantation.
Case description
A young White girl developed anti-topoisomerase-1-positive diffuse scleroderma aged 14 years with myositis. Pulmonary function tests were normal (forced vital capacity (FVC) of 88% predicted and diffusion of carbon monoxide (DLCO) was 95% predicted). Modified rodnan skin score progressed from 18/51 to 23/51 in the first few months of disease, and treatment was initiated on mycophenolate mofetil 1 g twice daily, methotrexate 7.5 mg weekly and periodic intravenous prostacyclin.
Computed tomography (CT) scan of the lungs showed a small area of subpleural interstitial thickening and groundglass change at the extreme right costophrenic angle suggestive of early interstitial lung disease.
Aged 17 years she developed raised troponin T of 0.207 mcg/L (normal range <0.03) and NTproBNP (155 pmol/L); 6-min walking distance was 341 m, and she had episodes of presyncope with effort. A timeline is shown in the following (Fig. 1) .
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Cardiac transplantation in a 20-year-old woman with scleroderma Cardiac magnetic resonance imaging (MRI) showed biventricular dysfunction with ejection fractions (EFs) of approximately 45% with linear basal septal mid-wall enhancement; 24-h electrocardiography (ECG) showed sinus rhythm with moderately frequent ventricular ectopics (678/24 h). She was treated with cyclophosphamide (750 mg intravenously monthly, approximately 500 mg/m 2 ) for 6 months.
A year later, she developed symptomatic ventricular tachycardias and dual-chamber implantable cardioverter-defibrillator (ICD) was inserted, and an appropriate shock was delivered 4 months after insertion.
By the age of 19 years, 6-min walking distance had fallen to 125 m. She felt dizzy and short of breath when walking with exertional chest tightness. Echocardiography showed EF of 15%-20% with dilated left ventricle (LV) and pericardial effusion. PET-CT was normal. She was initiated on standard cardiac therapies for LV systolic dysfunction including candesartan, carvedilol and spironolactone.
Myocardial biopsy showed extensive fatty replacement in one sample and replacement collagenous fibrosis in the other. She was treated with intravenous Rituximab. Despite therapy, she deteriorated with breathlessness while dressing and managed only 118 m in 6 min. She experienced increasing orthopnoea and peripheral oedema and was found to be in a low cardiac output state, requiring treatment with intravenous milrinone to maintain renal function. She was maintained on this medication and registered on the UK Urgent Heart Allocation Scheme. After 9 weeks, a heart became available and she underwent orthotopic cardiac transplantation, making an excellent post-operative recovery, and was discharged 16 days later with tacrolimus, mycophenolate mofetil and prednisolone. Histopathological examination of her heart showed extensive areas of subendocardial myocardial fibrosis in both ventricles, with prominence of arterioles from medial hypertrophy (Fig. 2) . A few lymphocytes were scattered within the myocardium and a few macrophages within areas of fibrosis but no vasculitis was seen, and coronary arteries were normal.
Over the first year, she has done well with improving exercise tolerance, New York Heart Association (NYHA) functional class I, normal cardiac function and no signs of disease recurrence on repeat biopsy. An episode of cytomegalovirus (CMV) viraemia and neutropaenia was treated with valganciclovir (while withholding mycophenolate).
Discussion
We have described a case of severe progressive cardiac involvement in a young woman with scleroderma. A recent comprehensive review of the literature on cardiac dis- Schreiber et al NP3 ease in scleroderma summarises studies of prevalence of cardiac abnormalities in scleroderma patients which have been described in several populations. However, case definitions have varied, and hence, prevalence estimates have also been quoted between 7% and 39% (3). It is the leading cause of death in juvenile onset diffuse cutaneous systemic sclerosis (4). The modified Medsge et al. (5) severity scale describes five grades of cardiac involvement from no involvement (normal ECG, left ventricular ejection fraction (LVEF) 55%), through mild (conduction defects on ECG, LVEF 45%-49%), moderate (arrhythmias on ECG, LVEF 40%-44%) and severe (arrhythmias requiring treatment on ECG, LVEF 30%-40%) to end-stage involvement (congestive heart failure (CHF), LVEF <30%). Higher grade was associated with increased mortality.
Using this definition, Steen and Medsger (6) reported that 15% of 913 patients with dcSSc in a prospective study developed severe heart disease, which they defined as cardiomyopathy with a decrease in LVEF and symptoms of CHF, symptomatic pericarditis (pericardial pain) and cardiac decompensation from effusion or arrhythmia attributable to SSc requiring treatment (6) .
Clinical features associated with myocardial involvement in a EUSTAR cohort; 7073 patients with SSc reported that LVEF <55% was independently associated with male gender, age, myositis, digital ulcers and lung involvement. Myositis was independently associated with a reduced LVEF (odds ratio (OR) = 2.88 (95% confidence interval (CI): 1.15, 7.19)) (7). However, ischaemic heart disease was a confounder factor which could not be accounted for.
Histopathologically, there appear to be two separate pathways. Cardiac involvement may be related to microvascular dysfunction and damage, leading to repeated focal ischaemic injury and irreversible myocardial fibrosis (8) , but it can also be due to a primary systemic myositic disease (9) . The pathology in our case showed extensive subendocardial myocardial fibrosis with prominence of arterioles from medial hypertrophy. These findings are similar to those reported in a recent series of cardiac biopsies from patients with scleroderma with cardiac involvement. In some cases, low-grade lymphocytic infiltration is also seen, providing evidence of a more active myositis. The medial hypertrophy of arterioles appears to be a common feature in SSc compared with other causes of myocardial fibrosis (10) . It may relate to a proliferative vasculopathy akin to that seen in pulmonary arterial hypertension rather than an active inflammatory myositis.
Cardiac involvement is associated with a poor prognosis, with up to 70% 5-year mortality (5, 11) .
There are no clinical studies of treatment for cardiac involvement in scleroderma. A group of British experts have summarised the literature on management produced management guidelines. They recommend moderate-dose corticosteroids (<15 mg/day) ± pulse cyclophosphamide as a reasonable approach if a myocarditis or other features of scleroderma cardiomyopathy are evident. Indications for the use of cyclophosphamide would thus include myocarditis, moderate-severe LV dysfunction (not secondary to atherosclerotic heart disease) and life-threatening cardiac arrhythmias (12) . The European Society of Cardiology recommends consideration of endomyocardial biopsy in patients with clinically suspected myocarditis and immunosuppressive treatment is indicated in biopsy-proven infection-negative myocarditis. They do not specify preferred medications (13) .
In our practice, for the treatment of patients with cardiac involvement due to scleroderma, we optimise standard cardiac therapy. We consider ICD insertion if there is a high burden of ventricular ectopics (>1000/24 h), non-sustained ventricular tachycardia, or symptomatic ventricular tachycardia.
We initiate immunosuppression with mycophenolate mofetil or cyclophosphamide if there is evidence of inflammation on cardiac MRI (T2 elevated) or immunohistochemistry, and once vital infection has been excluded with polymerase chain reaction from a myocardial biopsy. Where stability cannot be achieved refer for transplantation.
Case reports suggest that where evidence of inflammation either on histology or immunohistochemistry, favourable responses to immunosuppression with improvements in EF can occur.
Review of cases in the literature reveals two reports of cardiac transplant for scleroderma. A 14-year-old female developed acute heart failure 26 months after the transplant (14) , and a 36-year-old male had an excellent 1-year outcome (15) . Their details are presented in Tab. I.
The two previously described cases are instructive. The 14-year-old female had dominant left ventricular involvement similar to our patient. The 36-year-old man had less left ventricular failure but more involvement of the right ventricle. Symptoms were of NYHA grade III breathlessness in each case. Our patient had immunosuppression with methotrexate and cyclophosphamide and only with rituximab, which was note described in previous cases. The EF in our case was also lower than in previous cases. Our patient had diffuse disease and was anti-Scl-70 positive, while the previously reported cases had no scleroderma-specific antibodies.
In our case, heart transplantation was required because the patient had declining cardiac function, with progressive breathlessness and symptomatic arrhythmias despite maximal immunosuppression. There is no evidence to guide the timing of cardiac transplantation, but clearly it is only appropriate when other therapies have failed, when the underlying disease is deteriorating and when the risks of surgery have 
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Cardiac transplantation in a 20-year-old woman with scleroderma been carefully considered with a well-informed willing patient.
Conclusion
This case illustrates the potential severe and disproportionate cardiac involvement that occurs in poor prognosis juvenile onset diffuse cutaneous systemic sclerosis, in which cardiac involvement is the leading cause of death. Cardiac transplantation should be considered for patients with progressive cardiac failure due to scleroderma who have failed other measures.
